A strong and growing position on the parenteral market
The parenteral market is growing due to worldwide rise in general healthcare consumption and increasing development for complex diseases areas. SGD Pharma focuses its investment to support this dynamic market on mature and emerging zones :
- To widen its product offer, SGD Pharma enters into the tubular glass market through external growth.
- SGD Pharma strengthens its capabilities in pharmaceutical glass containers for injectable and infusion markets
- The R&D department imagines solutions easy-to-use in the new pharmaceutical facility format: Smaller-scale, flexible and multiproduct, these facilities use single-use technologies, continuous processing and modular design.
A global and patient-oriented player in the pharmaceutical primary packaging
SGD Pharma, Inspiring confidence.
With a global footprint and a strong sales force, SGD Pharma is recognised worldwide as a key player that customers can rely on to support new product development, day-to-day delivery, quality or regulatory support.
SGD Pharma benefits from a long know-how and a best-in-class manufacturing footprint. The company has a long-term investment plan to regularly leverage its manufacturing facilities and develop people competencies to be at the cutting edge of the technology. SGD Pharma commits to have the same standard in all its facilities. In 2016, all plants are certified according to ISO 15378 standard, pharma GMP’s compliant and equipped with ISO 8 clean rooms.